Revenue: As of FY2025 Q2, the actual value is USD 5.813 M.EPS: As of FY2025 Q2, the actual value is USD -0.09.EBIT: As of FY2025 Q2, the actual value is USD -12.63 M.<h3>Segment Revenue</h3><ul><li>Products Revenue: $11.243 million for the six months ended June 30, 2025, compared to $13.855 million for the same period in 2024, representing a decrease of 19%.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $39.188 million for the six months ended June 30, 2025, compared to $33.412 million for the same period in 2024, representing an increase in loss of 17%.</li><li>Loss from Operations: $47.589 million for the six months ended June 30, 2025, compared to $36.254 million for the same period in 2024, representing an increase in loss of 31%.</li><li>Research and Development Expenses: $6.579 million for the six months ended June 30, 2025, compared to $10.211 million for the same period in 2024, representing a decrease of 36%.</li><li>General and Administrative Expenses: $19.199 million for the six months ended June 30, 2025, compared to $21.264 million for the same period in 2024, representing a decrease of 10%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $15.733 million for the six months ended June 30, 2025, compared to - $31.697 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $0.665 million for the six months ended June 30, 2025, compared to $2.205 million provided by investing activities for the same period in 2024.</li><li>Net Cash Used in Financing Activities: - $4.485 million for the six months ended June 30, 2025, compared to $6.806 million provided by financing activities for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Impairment of Assets: $16.610 million for the six months ended June 30, 2025, compared to zero for the same period in 2024, due to the discharge of advance payments related to a take-or-pay agreement.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on scaling up its PET closures business, with plans to bring additional CapFormer Systems online and expand its manufacturing capacity. The strategic review initiated by the Board aims to explore alternatives to maximize shareholder value, including potential business combinations, equity and debt financing, and other strategic arrangements.</li><li>Non-Core Business: The company is evaluating strategic partnerships to finance the development of its closures manufacturing lines and is considering divestitures or technology licensing as part of its strategic review.</li></ul>

Origin Materials - CW26 | 10-Q: FY2025 Q2 Revenue: USD 5.813 M